Skip to main content
MLTX
NASDAQ Life Sciences

IZAR-1 Hits Week 16 Endpoints; Q3 Loss Wider Than Expected at $0.93/Share

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$11.6
Mkt Cap
$981.28M
52W Low
$9.46
52W High
$23.29
52W Position info
23% above low
Off High info
50% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

MLTX sits 23% above its 52-week low of $9.46.

Summary

MoonLake's Phase 3 IZAR-1 trial met its Week 16 endpoints, the key efficacy readout for sonelokimab in hidradenitis suppurativa. That follows the BLA submission disclosed in the September 30 8-K and keeps the FDA decision timeline intact. The Q3 print was messier: net loss of $79.5 million, or $0.93 per share, came in wider than the $0.78 consensus, though cash and short-term investments of $498.5 million fund operations into mid-2028. Next catalysts are IZAR-2 results in Q1 2027 and IZAR-1 Week 52 data in Q2 2027, with VELA-TEEN Phase 3 completing in Q4 2026 and reading out Q1 2027. A US launch of sonelokimab is planned for H2 2027 pending approval.

At the time of this announcement, MLTX was trading at $11.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $981.3M. The 52-week trading range was $9.46 to $23.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

MLTX - Latest Insights

MLTX
Nov 04, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.62
Real-time Price: $12.45 info
Change: +$0.8281 (+7%) info
Market Cap: $1.064B info
MLTX
Nov 04, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $12.45 info
Change: +$0.8381 (+7%) info
Market Cap: $1.064B info
MLTX
Sep 30, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.81
Real-time Price: $12.45 info
Change: +$0.6374 (+5%) info
Market Cap: $1.064B info
MLTX
Aug 10, 2026, 1:21 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $17.11
Real-time Price: $12.45 info
Change: -$4.66 (-27%) info
Market Cap: $1.064B info
MLTX
Aug 10, 2026, 7:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.19
Real-time Price: $12.45 info
Change: -$3.74 (-23%) info
Market Cap: $1.064B info